Urinary screening of elementary school students in Taicang, China

AbstractBackground: Chronic kidney disease in children is a severe progressive disease that influences the growth, development, and life quality of patients. This study aimed to explore the detection rate of proteinuria and hematuria in elementary school students in Taicang, China.Materials and methods: From 2015 to 2019, urine specimens were selected from 11,753 pupils in Taicang. The samples were tested for proteinuria and hematuria by applying single urine tests and urine sediment microscopic examinations. The observation results were divided into three groups: hematuria, proteinuria, and co-existing hematuria and proteinuria. In addition, kidney biopsies were carried out.Results: The positive rate of urinary abnormalities was 0.842% (99 cases), of which there were 51 cases (0.433%) of proteinuria, 42 cases (0.357%) of hematuria, and six cases (0.051%) of co-existing proteinuria and hematuria. In terms of gender, of the 99 cases, 63 were female students (1.142%) and 36 were male students (0.577%). Additionally, the age distribution results indicated that the prevalence of urine abnormalities in each age group from age 7 to age 13 were 11.11%, 12.12%, 12.12%, 16.16%, 29.29%, 18.18% and 3.03%, respectively. Furthermore, one immunoglobin A nephropathy case was certified by renal biopsy assay in the follow-up at six months.Conclusions: The urine screening revealed that abnormal proteinuria was the main form of urinary abnormalities in elementary school students from Taicang. Urine screening is necessary for early detection and intervention of kidney disease. [Ethiop. J. Health Dev. 2021; 35(2):91-96] Key words: Urine screening, Taicang, elementary school student, proteinuria, hematuri

Machine learning-based approach for efficient prediction of diagnosis, prognosis and lymph node metastasis of papillary thyroid carcinoma using adhesion signature selection

The association between adhesion function and papillary thyroid carcinoma (PTC) is increasingly recognized; however, the precise role of adhesion function in the pathogenesis and prognosis of PTC remains unclear. In this study, we employed the robust rank aggregation algorithm to identify 64 stable adhesion-related differentially expressed genes (ARDGs). Subsequently, using univariate Cox regression analysis, we identified 16 prognostic ARDGs. To construct PTC survival risk scoring models, we employed Lasso Cox and multivariate + stepwise Cox regression methods. Comparative analysis of these models revealed that the Lasso Cox regression model (LPSRSM) displayed superior performance. Further analyses identified age and LPSRSM as independent prognostic factors for PTC. Notably, patients classified as low-risk by LPSRSM exhibited significantly better prognosis, as demonstrated by Kaplan-Meier survival analyses. Additionally, we investigated the potential impact of adhesion feature on energy metabolism and inflammatory responses. Furthermore, leveraging the CMAP database, we screened 10 drugs that may improve prognosis. Finally, using Lasso regression analysis, we identified four genes for a diagnostic model of lymph node metastasis and three genes for a diagnostic model of tumor. These gene models hold promise for prognosis and disease diagnosis in PTC

SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models

Abstract Background Targeted estrogen receptor degradation has been approved to effectively treat ER + breast cancers. Due to the poor bioavailability of fulvestrant, the first generation of SERD, many efforts were made to develop oral SERDs. With the approval of Elacestrant, oral SERDs demonstrated superior efficacy than fulvestrant. However, due to the poor ability of known SERDs to penetrate the blood–brain barrier (BBB), breast cancer patients with brain metastasis cannot benefit from clinical SERDs. Methods The ER inhibitory effects were evaluated on ERα protein degradation, and target genes downregulation. And anti-proliferation activities were further determined in a panel of ER + breast cancer cell lines. The subcutaneous and intracranial ER + tumor models were used to evaluate the efficacy of anti-tumor effects. Brain penetrability was determined in multiple animal species. Results SCR-6852 is a novel SERD and currently is under early clinical evaluation. In vitro studies demonstrated that it strongly induced both wildtype and mutant ERα degradation. It potently inhibited cell proliferation in a panel of ER + breast cancer cell lines, including the cell lines containing ESR1 mutations (Y537 and D538). Furthermore, SCR-6852 exhibited pure antagonistic activities on the ERɑ signal axis identified both in vitro and in vivo. Oral administration of SCR-6852 at 10 mg/kg resulted in tumor shrinkage which was superior to Fulvestrant at 250 mg/kg, notably, in the intracranial tumor model, SCR-6852 effectively inhibited tumor growth and significantly prolonged mice survival, which correlated well with the high exposure in brains. In addition to mice, SCR-6852 also exhibited high brain penetrability in rats and dogs. Conclusions SCR-6852 is a novel SERD with high potency in inducing ERα protein degradation and pure antagonistic activity on ERɑ signaling in vitro and in vivo. Due to the high brain penetrability, SCR-6852 could be used to treat breast patients with brain metastasis